ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript Summary
ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript Summary
Cortrophin Gel generated $52.6 million in revenue, up 77% from the previous year.The following is a summary of the ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript:
以下是ani pharmaceuticals, inc. (anip) 2024年第三季度業績會交易會議記錄摘要：
Financial Performance:
財務業績:
ANI Pharmaceuticals reported third quarter revenues of $148.3 million, a 13% increase year-over-year.
Adjusted non-GAAP EBITDA and EPS were $35.1 million and $1.34 respectively.
Cortrophin Gel generated $52.6 million in revenue, up 77% from the previous year.
Generics business delivered $78.2 million in revenue, growing 11% year-over-year.
ani pharmaceuticals報告第三季度收入爲14830萬美元，同比增長13%。
調整後的非依據美國通用會計準則的EBITDA和EPS分別爲3510萬美元和1.34美元。
Cortrophin凝膠實現5260萬美元的營業收入，比上一年增長77%。
仿製藥業務實現7820萬美元的營業收入，同比增長11%。
Business Progress:
業務進展:
Successfully completed the acquisition of Alimera, enhancing the Rare Disease business.
Launched five new generics, contributing to solid performance in the base business.
Developed and submitted a supplemental NDA for a pre-filled syringe version of Cortrophin Gel, expected to launch in the first half of 2025.
成功完成了對Alimera的收購，增強了罕見疾病業務。
推出了五種新的仿製藥，爲基礎業務的穩健表現做出貢獻。
已開發並提交了Cortrophin Gel預填充注射器的補充新藥申請，預計將於2025年上半年推出。
Opportunities:
機會：
The integration of Alimera is expected to drive $35 million to $38 million in adjusted non-GAAP EBITDA for 2025, with the addition of ILUVIEN and YUTIQ expected to contribute significantly.
Projected growth from the enhanced ophthalmology sales team targeting additional Cortrophin revenues in 2025.
收購Alimera的整合預計將爲2025年的調整後非通用會計原則EBITDA帶來3500萬到3800萬美元的增長，而ILUVIEN和YUTIQ的加入有望產生顯著貢獻。
通過增強眼科銷售團隊，目標是在2025年從額外的Cortrophin收入中獲得增長。
Risks:
風險：
Implementing the integration of the acquired Alimera operations poses execution risks, although the initial stages have been reported as successful.
實施收購的Alimera運營的整合存在執行風險，儘管初期階段報告稱已成功進行。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
